ResearchApr 29, 2022
New risdiplam data shows long-term improvement in babies with Type 1 SMA
The latest data from the FIREFISH study of risdiplam was presented at the 14th European Paediatric Neurology Society (EPNS) Congress.
SMA Newsroom
Ukraine Apr 14, 2022
Update on Biogen's support to Ukrainian refugees
Biogen has provided us with a community statement to update our community on its work to support Ukrainian refugees, including those living with SMA.
OdySMAApr 8, 2022
OdySMA – a quest to access – Teaser Website goes live!
We are happy to announce, that today the teaser of our OdySMA project goes live.
OdySMA is an initiative to reveal the “quest to access” of people living with SMA by mapping, visualising and centralising knowledge and data around access issues.
ResearchMar 16, 2022
New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with SMA
Latest risdiplam (Evrysdi) data updates, which were presented at the 2022 MDA Clinical and Scientific Conference on 13th - 16th March.